Understanding how HIV-1 Vpu and HIV-2 Env stimulate virus release
Understanding how HIV-1 Vpu and HIV-2 Env stimulate virus release
批准号:
8110215
负责人:
Paula M Cannon
金额:
$8.45万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-08-18 至 2011-07-31
关键词:
Acquired Immunodeficiency SyndromeAffectAnti-HIV AgentsAnti-HIV TherapyBiochemicalBiologyCell LineCell physiologyCell surfaceCellsCellular StructuresCodeComplementary DNAComplexCytoplasmic TailDataEmployee StrikesEnhancersEnsureGaggingGene ExpressionGoalsHIVHIV InfectionsHIV-1HIV-2HandHela CellsHomologous GeneHumanHuman CloningImmunofluorescence ImmunologicIon ChannelKnowledgeLentivirus VectorLibrariesLocationLymphocyteMacacaMapsMediatingMembraneMicroarray AnalysisModelingMolecularMurine leukemia virusOpen Reading FramesPathogenicityPathologyPathway interactionsPatientsPhenotypePlayPopulationPrimate LentivirusesPrincipal InvestigatorProcessProductionPropertyProteinsPublic HealthRecruitment ActivityResearchRetroviral VectorRetroviridaeRoleSIVScreening procedureSiteSmall Interfering RNASpecificitySuggestionTestingTherapeutic InterventionTimeViralViral ProteinsVirusVirus Assemblybasecell typecellular targetingdrug developmentenv Gene Productsenv Glycoproteinsgag Gene Productsin vivomacrophagemurine retroviral vectorparticleprogramstraffickingvector genomevpu Protein
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Primate lentiviruses code for a conserved function that is necessary for the efficient production of viral
particles and in vivo pathogenicity. For HIV-1 this is carried out by the accessory protein Vpu, while for HIV-2,
the function has been mapped to the Env glycoprotein. In addition, our studies with the simple retrovirus,
murine leukemia virus (MLV), have identified a similar activity in its Env protein. We have found that all three of
these enhancers of virus release (EVRs) can boost the production of heterologous retroviruses, suggesting
that they act on the general cellular pathways involved in retrovirus budding. Analysis of EVR-responsive and
non-responsive cell lines has led to the suggestion that human cells contain a natural restriction factor that
suppresses retrovirus budding and which the EVRs have evolved to counteract. Therefore, it is our central
hypothesis that EVR function is a conserved and important activity for retroviruses in general.
Although the EVR activity of Vpu was first described in 1989, the mechanism whereby it enhances virus
release is still unknown and represents a significant gap in our knowledge of HIV biology. Even less is
understood about the HIV-2 Env activity, which shows both similarities and striking differences with Vpu. The
research plan outlined in this proposal will take a comprehensive approach to studying retroviral EVRs, both in
order to identify the functional domains of the viral proteins involved, and to understand the host cell processes
that are the targets of their activity. Using the three different EVRs that we have identified, we will precisely
define the functional domains within these proteins and assess whether they have the same cellular target and
activity, or whether a common EVR phenotype is achieved through different pathways. We will also take
advantage of a non-Vpu-responsive HeLa cell line that we have identified, which retains the ability to respond
to the HIV-2 Env EVR. Preliminary studies of this cell lines are already suggesting a mechanism for Vpu `s
activity. We will directly examine how EVRs affect virus assembly and budding and their influence on cellular
trafficking pathways, using a combination of microarray, biochemical and immunofluorescence approaches.
Finally, we will attempt to clone the human cell restriction factor using approaches based on the microarray
analysis of complex cDNA and siRNA libraries.
Relevance of research to public health: HIV infection and AIDS continue to be a major public health problem,
with anti-HIV drugs only available against limited viral targets. The HIV-1 Vpu protein is essential for HIV
pathogenicity but its mechanism of action is unclear. It is our goal to investigate the mechanism behind this
important HIV function and thereby identify new targets for drug development.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1186/1742-4690-7-13
发表时间:
2010-02-18
期刊:
Retrovirology
影响因子:
3.3
作者:
[Yang SJ, Lopez LA, Hauser H, Exline CM, Haworth KG, Cannon PM]
通讯作者:
Cannon PM
DOI:
10.1186/s12977-015-0194-0
发表时间:
2015-08-07
期刊:
Retrovirology
影响因子:
3.3
作者:
[Exline CM, Yang SJ, Haworth KG, Rengarajan S, Lopez LA, Droniou ME, Seclen E, Cannon PM]
通讯作者:
Cannon PM
DOI:
10.1186/1742-4690-8-78
发表时间:
2011-09-28
期刊:
Retrovirology
影响因子:
3.3
作者:
[Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM]
通讯作者:
Cannon PM
Nuclear receptor regulation of epigenetic mechanisms regulating HIV CNS latency
-
批准号:10747002
-
项目类别:
-
资助金额:$74.52万
-
财政年份:2023
-
负责人:Paula M Cannon
-
依托单位:
Gene edited B cells to co-express CNS-targeted antibodies
-
批准号:10475527
-
项目类别:
-
资助金额:$20.63万
-
财政年份:2022
-
负责人:Paula M Cannon
-
依托单位:
Gene edited B cells to co-express CNS-targeted antibodies
-
批准号:10589115
-
项目类别:
-
资助金额:$24.75万
-
财政年份:2022
-
负责人:Paula M Cannon
-
依托单位:
Combination gene editing for local and systemic HIV resistance
-
批准号:10601081
-
项目类别:
-
资助金额:$51.91万
-
财政年份:2020
-
负责人:Paula M Cannon
-
依托单位:
Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure
-
批准号:10163906
-
项目类别:
-
资助金额:$265.82万
-
财政年份:2020
-
负责人:Paula M Cannon
-
依托单位:
Combination gene editing for local and systemic HIV resistance
-
批准号:10163911
-
项目类别:
-
资助金额:$39.65万
-
财政年份:2020
-
负责人:Paula M Cannon
-
依托单位:
Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure
-
批准号:9891825
-
项目类别:
-
资助金额:$308.51万
-
财政年份:2020
-
负责人:Paula M Cannon
-
依托单位:
Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure
-
批准号:10601061
-
项目类别:
-
资助金额:$352.85万
-
财政年份:2020
-
负责人:Paula M Cannon
-
依托单位:
Administrative Core
-
批准号:10601062
-
项目类别:
-
资助金额:$34.57万
-
财政年份:2020
-
负责人:Paula M Cannon
-
依托单位:
Administrative Core
-
批准号:10409801
-
项目类别:
-
资助金额:$33.59万
-
财政年份:2020
-
负责人:Paula M Cannon
-
依托单位:
Combination gene editing for local and systemic HIV resistance
-
批准号:10409805
-
项目类别:
-
资助金额:$49.38万
-
财政年份:2020
-
负责人:Paula M Cannon
-
依托单位:
Administrative Core
-
批准号:10163907
-
项目类别:
-
资助金额:$24.3万
-
财政年份:2020
-
负责人:Paula M Cannon
-
依托单位:
Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure
-
批准号:10409800
-
项目类别:
-
资助金额:$297.85万
-
财政年份:2020
-
负责人:Paula M Cannon
-
依托单位:
Next Generation HSC Gene Therapy for HIV Control and Eradication
-
批准号:9262291
-
项目类别:
-
资助金额:$251.45万
-
财政年份:2015
-
负责人:Paula M Cannon
-
依托单位:
Next Generation HSC Gene Therapy for HIV Control and Eradication
-
批准号:9126001
-
项目类别:
-
资助金额:$22.84万
-
财政年份:2015
-
负责人:Paula M Cannon
-
依托单位:
HIV-specific nucleases to reservoir cells
-
批准号:8656306
-
项目类别:
-
资助金额:$20.52万
-
财政年份:2013
-
负责人:Paula M Cannon
-
依托单位:
HIV-specific nucleases to reservoir cells
-
批准号:9437666
-
项目类别:
-
资助金额:$49.5万
-
财政年份:2013
-
负责人:Paula M Cannon
-
依托单位:
HIV-specific nucleases to reservoir cells
-
批准号:8774195
-
项目类别:
-
资助金额:$22.53万
-
财政年份:2013
-
负责人:Paula M Cannon
-
依托单位:
Targeting the Entry Pathway of New World Arenaviruses for Anitviral Threraputics
-
批准号:8260252
-
项目类别:
-
资助金额:$36.66万
-
财政年份:2011
-
负责人:Paula M Cannon
-
依托单位:
Targeting the Entry Pathway of New World Arenaviruses for Anitviral Threraputics
-
批准号:7675170
-
项目类别:
-
资助金额:$35.19万
-
财政年份:2009
-
负责人:Paula M Cannon
-
依托单位:
海外基金